tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Nov 1;S1201-9712(22)00580-X.
doi: 10.1016/j.ijid.2022.10.041. Online ahead of print.
Relative effectiveness of the adjuvanted versus non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults
Alexander Domnich[SUP] 1 [/SUP], Donatella Panatto[SUP] 2 [/SUP], Elena Pariani[SUP] 3 [/SUP], Christian Napoli[SUP] 4 [/SUP], Maria Chironna[SUP] 5 [/SUP], Ilaria Manini[SUP] 6 [/SUP], Caterina Rizzo[SUP] 7 [/SUP], Andrea Orsi[SUP] 2 [/SUP], Giancarlo Icardi[SUP] 2 [/SUP], IT-BIVE-HOSP Network Study Group
Affiliations
Abstract
Objectives: In this study, we aimed to investigate the relative vaccine effectiveness (rVE) of the MF59-adjuvanted trivalent (aTIV) and non-adjuvanted quadrivalent (QIVe) egg-based standard-dose vaccines against severe laboratory-confirmed influenza.
Methods: This test-negative case-control study was conducted in hospital setting during four recent Italian influenza seasons (from 2018/19 to 2021/22). The clinical outcome was severe acute respiratory infection (SARI) with laboratory confirmation diagnosed among subjects aged ≥ 65 years. rVE of aTIV versus QIVe was estimated through propensity score matching followed by logistic regression.
Results: Influenza virus circulated to a significant extent only during the 2018/19 and 2019/20 seasons. The final population included 512 vaccinated older adults, of which 83 were cases and 429 were test-negative controls. aTIV and QIVe users differed substantially from the point of view of several baseline characteristics. The propensity-score adjusted rVE of aTIV vs QIVe was 59.2% (95% CI: 14.6%, 80.5%), 54.7% (95% CI: -28.7%, 84.0%) and 56.9% (95% CI: -7.8%, 82.8%) against any influenza, A(H1N1)pdm09 and A(H3N2), respectively.
Conclusions: aTIV was more effective than QIVe in preventing laboratory-confirmed SARI. Benefits of aTIV may be obscured by confounding by indication.
Keywords: Adjuvanted influenza vaccine; Influenza; Influenza vaccines; Older adults; Vaccine effectiveness.
. 2022 Nov 1;S1201-9712(22)00580-X.
doi: 10.1016/j.ijid.2022.10.041. Online ahead of print.
Relative effectiveness of the adjuvanted versus non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults
Alexander Domnich[SUP] 1 [/SUP], Donatella Panatto[SUP] 2 [/SUP], Elena Pariani[SUP] 3 [/SUP], Christian Napoli[SUP] 4 [/SUP], Maria Chironna[SUP] 5 [/SUP], Ilaria Manini[SUP] 6 [/SUP], Caterina Rizzo[SUP] 7 [/SUP], Andrea Orsi[SUP] 2 [/SUP], Giancarlo Icardi[SUP] 2 [/SUP], IT-BIVE-HOSP Network Study Group
Affiliations
- PMID: 36332902
- DOI: 10.1016/j.ijid.2022.10.041
Abstract
Objectives: In this study, we aimed to investigate the relative vaccine effectiveness (rVE) of the MF59-adjuvanted trivalent (aTIV) and non-adjuvanted quadrivalent (QIVe) egg-based standard-dose vaccines against severe laboratory-confirmed influenza.
Methods: This test-negative case-control study was conducted in hospital setting during four recent Italian influenza seasons (from 2018/19 to 2021/22). The clinical outcome was severe acute respiratory infection (SARI) with laboratory confirmation diagnosed among subjects aged ≥ 65 years. rVE of aTIV versus QIVe was estimated through propensity score matching followed by logistic regression.
Results: Influenza virus circulated to a significant extent only during the 2018/19 and 2019/20 seasons. The final population included 512 vaccinated older adults, of which 83 were cases and 429 were test-negative controls. aTIV and QIVe users differed substantially from the point of view of several baseline characteristics. The propensity-score adjusted rVE of aTIV vs QIVe was 59.2% (95% CI: 14.6%, 80.5%), 54.7% (95% CI: -28.7%, 84.0%) and 56.9% (95% CI: -7.8%, 82.8%) against any influenza, A(H1N1)pdm09 and A(H3N2), respectively.
Conclusions: aTIV was more effective than QIVe in preventing laboratory-confirmed SARI. Benefits of aTIV may be obscured by confounding by indication.
Keywords: Adjuvanted influenza vaccine; Influenza; Influenza vaccines; Older adults; Vaccine effectiveness.